Recent advances in active hepatic targeting drug delivery system

Current Drug Targets

Volumn 15, Issue 6, 2014, Pages 573-599

  Wang, Yang ^a   Du, Hongliang ^a   Zhai, Guangxi ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

Active hepatic targeting; Drug carriers; Drug delivery; Homing ligands

Indexed keywords

ALGINIC ACID; APOFERRITIN; ASIALOFETUIN; BRUCINE; CERAMIDE; CHITOSAN; COPOLYMER; CURCUMIN; DOXORUBICIN; GALACTOSE; GLYCOPROTEIN; HYALURONIC ACID; LACTOSE; LIPOSOME; MIRIPLATIN; N ACETYLGALACTOSAMINE; NORCANTHARIDIN; PACLITAXEL; PEGARGIMINASE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PENTOXIFYLLINE; POLYAMIDOAMINE; POLYETHYLENEIMINE; POLYLYSINE; POLYPEPTIDE; SCAVENGER RECEPTOR; SELENIUM; UNINDEXED DRUG; ZINOSTATIN MALEIC ACID STYRENE COPOLYMER; ANTINEOPLASTIC AGENT; DRUG CARRIER;

ARTICLE; BLADDER IRRITATION; BLOOD BRAIN BARRIER; CHEMICAL STRUCTURE; CHRONIC HEPATITIS; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG TARGETING; GENE EXPRESSION; HUMAN; HYDROPHOBICITY; KINETICS; LIVER CANCER; LIVER DISEASE; MICELLE; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); TUMOR GROWTH; ANIMAL; CARCINOMA, HEPATOCELLULAR; LIVER NEOPLASMS; PROCEDURES;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS; LIVER NEOPLASMS;

EID: 84899814901     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/1389450115666140309232100     Document Type: Article

References (200)

1. Zhang H, Ma Y, Sun XL. Recent developments in carbohydratedecorated targeted drug/gene delivery. Med Res Rev 2010; 30: 270-89.
2. Rozema DB, Lewis DL, Wakefield DH, et al. Dynamic PolyConjugates for targeted in vivo delivery of siRNA to hepatocytes. Proc Natl Acad Sci USA 2007; 104: 12982-7.
3. Snoeys J, Lievens J, Wisse E, et al. Species differences in transgene DNA uptake in hepatocytes after adenoviral transfer correlate with the size of endothelial fenestrae. Gene Ther 2007; 14: 604-12.
4. Maeda H, Sawa T, Konno T. Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS. J Control Release 2001; 74: 47-61.
5. Poelstra K, Prakash J, Beljaars L. Drug targeting to the diseased liver. J Control Release 2012; 161: 188-97.
6. Jain K, Kesharwani P, Gupta U, Jain NK. A review of glycosylated carriers for drug delivery. Biomaterials 2012; 33: 4166-86.
7. Chan TM, Ho SK, Tang CS, et al. Pilot study of pegylated interferon-alpha 2a in dialysis patients with chronic hepatitis C virus infection. Nephrology 2007; 12: 11-7.
8. Youngster S, Wang YS, Grace M, et al. Structure, biology, and therapeutic implications of pegylated interferon alpha-2b. Curr Pharm Des 2002; 8: 2139-57.
9. Glazer ES, Piccirillo M, Albino V, et al. Phase II study of pegylated arginine deiminase for nonresectable and metastatic hepatocellular carcinoma. J Clin Oncol 2010; 28: 2220-6.
10. Okusaka T, Kasugai H, Ishii H, et al. A randomized phase II trial of intra-arterial chemotherapy using SM-11355 (Miriplatin) for hepatocellular carcinoma. Invest New Drugs 2012; 30: 2015-25.
11. Tabernero J, Shapiro GI, LoRusso PM, et al. First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement. Cancer Discov 2013; 3: 406-17.
12. Seymour LW, Ferry DR, Anderson D, et al. Hepatic drug targeting: phase I evaluation of polymer-bound doxorubicin. J Clin Oncol 2002; 20: 1668-76.
13. Cook SE, Park IK, Kim EM, et al. Galactosylated polyethylenimine-graft-poly(vinyl pyrrolidone) as a hepatocytetargeting gene carrier. J Control Release 2005; 105: 151-63.
14. Diebold SS, Kursa M, Wagner E, Cotten M, Zenke M. Mannose polyethylenimine conjugates for targeted DNA delivery into dendritic cells. J Biol Chem 1999; 274: 19087-94.
15. Higuchi Y, Nishikawa M, Kawakami S, Yamashita F, Hashida M. Uptake characteristics of mannosylated and fucosylated bovine serum albumin in primary cultured rat sinusoidal endothelial cells and Kupffer cells. Int J Pharm 2004; 287: 147-54.
16. Platt VM, Szoka FC, Jr. Anticancer therapeutics: targeting macromolecules and nanocarriers to hyaluronan or CD44, a hyaluronan receptor. Mol Pharm 2008; 5: 474-86.
17. Varghese OP, Sun W, Hilborn Jn, Ossipov DA. In Situ Cross-Linkable High Molecular Weight Hyaluronan-Bisphosphonate Conjugate for Localized Delivery and Cell-Specific Targeting: A Hydrogel Linked Prodrug Approach. J Am Chem Soc 2009; 131: 8781-3.
18. Atzori L, Poli G, Perra A. Hepatic stellate cell: a star cell in the liver. Int J Biochem Cell Biol 2009; 41: 1639-42.
19. Motoyama K, Nakashima Y, Aramaki Y, et al. In vitro Gene Delivery Mediated by Asialofetuin-Appended Cationic Liposomes Associated with gamma-Cyclodextrin into Hepatocytes. J Drug Deliv 2011; 2011: 476137.
20. Dasí F, Benet M, Crespo J, Crespo A, Aliño S. Asialofetuin liposome-mediated human α1-antitrypsin gene transfer in vivo results in stationary long-term gene expression. J Mol Med 2001; 79: 205-12.
21. Zhu L, Mahato RI. Targeted delivery of siRNA to hepatocytes and hepatic stellate cells by bioconjugation. Bioconjug Chem 2010; 21: 2119-27.
22. Lee MH, Han JH, Kwon PS, et al. Hepatocyte-targeting single galactose-appended naphthalimide: a tool for intracellular thiol imaging in vivo. J Am Chem Soc 2012; 134: 1316-22.
23. Ding J, Xiao C, Li Y, et al. Efficacious hepatoma-targeted nanomedicine self-assembled from galactopeptide and doxorubicin driven by two-stage physical interactions. J Control Release 2013; 169: 193-203.
24. Guo B, Cheng Y, Li N, et al. In vitro and in vivo studies of galactose-modified liver-targeting liposomes. J Drug Target 2012.
25. Medina SH, Tekumalla V, Chevliakov MV, et al. Nacetylgalactosamine-functionalized dendrimers as hepatic cancer cell-targeted carriers. Biomaterials 2011; 32: 4118-29.
26. Arima H, Yamashita S, Mori Y, et al. In vitro and in vivo gene delivery mediated by Lactosylated dendrimer/alpha-cyclodextrin conjugates (G2) into hepatocytes. J Control Release 2010; 146: 106-17.
27. Motoyama K, Mori Y, Yamashita S, et al. In vitro gene delivery mediated by lactosylated dendrimer (generation 3, G3)/α-cyclodextrin conjugates into hepatocytes. J Incl Phenom Macrocycl Chem 2010; 70: 333-8.
28. Hayashi Y, Mori Y, Yamashita S, et al. Potential use of lactosylated dendrimer (G3)/alpha-cyclodextrin conjugates as hepatocyte-specific siRNA carriers for the treatment of familial amyloidotic polyneuropathy. Mol Pharm 2012; 9: 1645-53.
29. Hasegawa T, Umeda M, Matsumoto T, et al. Lactose-appended schizophyllan is a potential candidate as a hepatocyte-targeted antisense carrier. Chem Commun (Camb) 2004: 382-3.
30. Kamruzzaman Selim KM, Ha YS, Kim SJ, et al. Surface modification of magnetite nanoparticles using lactobionic acid and their interaction with hepatocytes. Biomaterials 2007; 28: 710-6.
31. Kamruzzaman Selim KM, Xing ZC, Guo H, Kang IK. Immobilization of lactobionic acid on the surface of cadmium sulfide nanoparticles and their interaction with hepatocytes. J Mater Sci Mater Med 2009; 20: 1945-53.
32. Wang Q, Zhang L, Hu W, et al. Norcantharidin-associated galactosylated chitosan nanoparticles for hepatocyte-targeted delivery. Nanomedicine 2010; 6: 371-81.
33. Zhang X, Zhang X, Yu P, et al. Hydrotropic polymeric mixed micelles based on functional hyperbranched polyglycerol copolymers as hepatoma-targeting drug delivery system. J Pharm Sci 2013; 102: 145-53.
34. Choi YH, Liu F, Park JS, Kim SW. Lactose-poly(ethylene glycol)-grafted poly-L-lysine as hepatoma cell-tapgeted gene carrier. Bioconjug Chem 1998; 9: 708-18.
35. Huang F-W, Yang J, Feng J, Zhuo R-X, Zhang X-Z. Design of hepatocyte-targeted gene transfer vector and its in vitro transfer of tumor-suppressor p53 gene. J Mater Chem 2011; 21: 3585.
36. Seo SJ, Akaike T, Choi YJ, et al. Alginate microcapsules prepared with xyloglucan as a synthetic extracellular matrix for hepatocyte attachment. Biomaterials 2005; 26: 3607-15.
37. von Schantz L, Gullfot F, Scheer S, et al. Affinity maturation generates greatly improved xyloglucan-specific carbohydrate binding modules. BMC Biotechnol 2009; 9: 92.
38. Guo BH, Cheng Y, Lin LP, Lin DH, Wu W. Preparation and characterization of galactose-modified liposomes by a nonaqueous enzymatic reaction. J Liposome Res 2011; 21: 255-60.
39. Huang W, Wang W, Wang P, et al. Glycyrrhetinic acidfunctionalized degradable micelles as liver-targeted drug carrier. J Mater Sci Mater Med 2011; 22: 853-63.
40. Chen Z-P, Xiao L, Liu D, et al. Synthesis of a novel polymer cholesterol-poly(ethylene glycol) 2000-glycyrrhetinic acid (chol-PEG-GA) and its application in brucine liposome. J Appl Polym Sci 2011; 124: 4554-63.
41. Zhang C, Wu Y, Liu T, et al. Antitumor activity of drug loaded glycyrrhetinic acid modified alginate nanoparticles on mice bearing orthotopic liver tumor. J Control Release 2011; 152 Suppl 1: e111-3.
42. Tian Q, Wang XH, Wang W, et al. Self-assembly and liver targeting of sulfated chitosan nanoparticles functionalized with glycyrrhetinic acid. Nanomedicine 2012; 8: 870-9.
43. Tian Q, Wang X, Wang W, et al. Insight into glycyrrhetinic acid: the role of the hydroxyl group on liver targeting. Int J Pharm 2010; 400: 153-7.
44. Cho HJ, Yoon HY, Koo H, et al. Self-assembled nanoparticles based on hyaluronic acid-ceramide (HA-CE) and Pluronic(R) for tumor-targeted delivery of docetaxel. Biomaterials 2011; 32: 7181-90.
45. Cho HJ, Yoon IS, Yoon HY, et al. Polyethylene glycol-conjugated hyaluronic acid-ceramide self-assembled nanoparticles for targeted delivery of doxorubicin. Biomaterials 2012; 33: 1190-200.
46. He M, Zhao Z, Yin L, Tang C, Yin C. Hyaluronic acid coated poly(butyl cyanoacrylate) nanoparticles as anticancer drug carriers. Int J Pharm 2009; 373: 165-73.
47. Jeong YI, Kim do H, Chung CW, et al. Self-assembled nanoparticles of hyaluronic acid/poly(DL-lactide-co-glycolide) block copolymer. Colloid Surface B 2012; 90: 28-35.
48. Liu Y, Sun J, Cao W, et al. Dual targeting folate-conjugated hyaluronic acid polymeric micelles for paclitaxel delivery. Int J Pharm 2011; 421: 160-9.
49. Ren Y, Zhao T, Mao G, et al. Antitumor activity of hyaluronic acid-selenium nanoparticles in Heps tumor mice models. Int J Biol Macromol 2013; 57: 57-62.
50. Saravanakumar G, Choi KY, Yoon HY, et al. Hydrotropic hyaluronic acid conjugates: Synthesis, characterization, and implications as a carrier of paclitaxel. Int J Pharm 2010; 394: 154-61.
51. Yang XY, Li YX, Li M, et al. Hyaluronic acid-coated nanostructured lipid carriers for targeting paclitaxel to cancer. Cancer Lett 2013; 334: 338-45.
52. Lee H, Kim SI, Shin D, et al. Hepatic siRNA delivery using recombinant human apolipoprotein A-I in mice. Biochem Biophys Res Commun 2009; 378: 192-6.
53. Shin JY, Yang Y, Heo P, et al. pH-responsive high-density lipoprotein-like nanoparticles to release paclitaxel at acidic pH in cancer chemotherapy. Int J Nanomedicine 2012; 7: 2805-16.
54. Cutrin JC, Crich SG, Burghelea D, Dastru W, Aime S. Curcumin/Gd loaded apoferritin: a novel "theranostic" agent to prevent hepatocellular damage in toxic induced acute hepatitis. Mol Pharm 2013; 10: 2079-85.
55. Makino A, Harada H, Okada T, et al. Effective encapsulation of a new cationic gadolinium chelate into apoferritin and its evaluation as an MRI contrast agent. Nanomedicine 2011; 7: 638-46.
56. Vickers KC, Palmisano BT, Shoucri BM, Shamburek RD, Remaley AT. MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat Cell Biol 2011; 13: 423-33.
57. Yuan Y, Wang W, Wang B, et al. Delivery of hydrophilic drug doxorubicin hydrochloride-targeted liver using apoAI as carrier. J Drug Target 2013; 21: 367-74.
58. Ishiwatari H, Sato Y, Murase K, et al. Treatment of pancreatic fibrosis with siRNA against a collagen-specific chaperone in vitamin A-coupled liposomes. Gut 2013; 62: 1328-39.
59. Narmada BC, Kang Y, Venkatraman L, et al. Hepatic stellate celltargeted delivery of hepatocyte growth factor transgene via bile duct infusion enhances its expression at fibrotic foci to regress dimethylnitrosamine-induced liver fibrosis. Hum Gene Ther 2013; 24: 508-19.
60. Hagens WI, Mattos A, Greupink R, et al. Targeting 15dprostaglandin J2 to hepatic stellate cells: two options evaluated. Pharm Res 2007; 24: 566-74.
61. Sato Y, Murase K, Kato J, et al. Resolution of liver cirrhosis using vitamin A-coupled liposomes to deliver siRNA against a collagenspecific chaperone. Nat Biotechnol 2008; 26: 431-42.
62. Prakash J, de Jong E, Post E, et al. A novel approach to deliver anticancer drugs to key cell types in tumors using a PDGF receptor-binding cyclic peptide containing carrier. J Control Release 2010; 145: 91-101.
63. Prakash J, Beljaars L, Harapanahalli AK, et al. Tumor-targeted intracellular delivery of anticancer drugs through the mannose-6-phosphate/insulin-like growth factor II receptor. Int J Cancer 2010; 126: 1966-81.
64. Kim SJ, Ise H, Goto M, et al. Gene delivery system based on highly specific recognition of surface-vimentin with Nacetylglucosamine immobilized polyethylenimine. Biomaterials 2011; 32: 3471-80.
65. Du SL, Pan H, Lu WY, et al. Cyclic Arg-Gly-Asp peptide-labeled liposomes for targeting drug therapy of hepatic fibrosis in rats. J Pharmacol Exp Ther 2007; 322: 560-8.
66. Li F, Sun JY, Wang JY, et al. Effect of hepatocyte growth factor encapsulated in targeted liposomes on liver cirrhosis. J Control Release 2008; 131: 77-82.
67. Hirata K, Maruyama T, Watanabe H, et al. Genetically engineered mannosylated-human serum albumin as a versatile carrier for liverselective therapeutics. J Control Release 2010; 145: 9-16.
68. Harris RL, van den Berg CW, Bowen DJ. ASGR1 and ASGR2, the Genes that Encode the Asialoglycoprotein Receptor (Ashwell Receptor), Are Expressed in Peripheral Blood Monocytes and Show Interindividual Differences in Transcript Profile. Mol Biol Int 2012; 2012: 283974.
69. Gupta A. Asialoglycoprotein Receptor and the Macrophage Galactose-Type Lectin. In: Gupta G, editor. Wien: Springer Vienna 2012. p. 709-24.
70. Bider MD, Wahlberg JM, Kammerer RA, Spiess M. The oligomerization domain of the asialoglycoprotein receptor preferentially forms 2:2 heterotetramers in vitro. J Biol Chem 1996; 271: 31996-2001.
71. Schwartz AL, Rup D, Lodish HF. Difficulties in the quantification of asialoglycoprotein receptors on the rat hepatocyte. J Biol Chem 1980; 255: 9033-6.
72. Gupta RK, Gupta G. Chi-Lectins: Forms, Functions and Clinical Applications. Springer 2012. p. 421-37.
73. Colquhoun SD, Connelly CA, Vera DR. Portal-Systemic shunts reduce asialoglycoprotein receptor density in rats. J Nucl Med 2001; 42: 110-6.
74. Ramadugu SK, Chung YH, Fuentes EJ, Rice KG, Margulis CJ. In silico prediction of the 3D structure of trimeric asialoglycoprotein receptor bound to triantennary oligosaccharide. J Am Chem Soc 2010; 132: 9087-95.
75. Leclercq F, Dubertret C, Pitard B, Scherman D, Herscovici J. Synthesis of glycosylated polyethylenimine with reduced toxicity and high transfecting efficiency. Bioorg Med Chem Lett 2000; 10: 1233-5.
76. Young SP, Bomford A, Williams R. Dual pathways for the uptake of rat asialotransferrin by rat hepatocytes. J Biol Chem 1983; 258: 4972-6.
77. Pathak A, Vyas SP, Gupta KC. Nano-vectors for efficient liver specific gene transfer. Int J Nanomedicine 2008; 3: 31-49.
78. Watanabe Y, Liu X, Shibuya I, Akaike T. Functional evaluation of poly-(N-p-vinylbenzyl-O-beta-D-galactopyranosyl-[1-4]-Dgluconamide)(PVLA) as a liver specific carrier. J Biomater Sci Polym Ed 2000; 11: 833-48.
79. Rensen PC, Sliedregt LA, Ferns M, et al. Determination of the upper size limit for uptake and processing of ligands by the asialoglycoprotein receptor on hepatocytes in vitro and in vivo. J Biol Chem 2001; 276: 37577-84.
80. Lee RT, Lee YC. Affinity enhancement by multivalent lectin-carbohydrate interaction. Glycoconjugate journal 2000; 17: 543-51.
81. Yang Y, Zhao Y-T, Yan T-T, et al. Design and fabrication of multivalent Gal-containing quantum dots and study of its interactions with asialoglycoprotein receptor (ASGP-R). Tetrahedron Lett 2010; 51: 4182-5.
82. Cai G, Jiang M, Zhang B, et al. Preparation and biological evaluation of a glycosylated fusion interferon directed to hepatic receptors. Biol Pharm Bull 2009; 32: 440-3.
83. Cai G, Jiang M, Zhou Y, et al. Generation of a liver targeting fusion interferon and its bioactivity analysis in vitro. Pharmazie 2011; 66: 761-5.
84. Suriano F, Pratt R, Tan JP, et al. Synthesis of a family of amphiphilic glycopolymers via controlled ring-opening polymerization of functionalized cyclic carbonates and their application in drug delivery. Biomaterials 2010; 31: 2637-45.
85. Jain NK, Jain SK. Development and in vitro characterization of galactosylated low molecular weight chitosan nanoparticles bearing doxorubicin. AAPS PharmSciTech 2010; 11: 686-97.
86. Suo A, Qian J, Yao Y, Zhang W. Galactosylated poly(ethylene glycol)-b-poly (l-lactide-co-beta-malic acid) block copolymer micelles for targeted drug delivery: preparation and in vitro characterization. Int J Nanomedicine 2010; 5: 1029-38.
87. Guo L, Huang J, Zheng LM. Bifunctional bacterial magnetic nanoparticles for tumor targeting. Nanoscale 2012; 4: 879-84.
88. Wang YC, Liu XQ, Sun TM, Xiong MH, Wang J. Functionalized micelles from block copolymer of polyphosphoester and poly(epsilon-caprolactone) for receptor-mediated drug delivery. J Control Release 2008; 128: 32-40.
89. Zhang W, Liu Y, Chen X-Y, et al. Two modelling data analytical methods applied to optimise the preparation of norcantharidin chitosan nanoparticles. J Exp Nanosci 2010; 5: 271-84.
90. Bei YY, Chen XY, Liu Y, et al. Novel norcantharidin-loaded liver targeting chitosan nanoparticles to enhance intestinal absorption. Int J Nanomedicine 2012; 7: 1819-27.
91. Hai L, Zhang Z-R, Wang S, Xiao X, Wu Y. Synthesis of Multivalent Galactosides as Targeting Ligand for Gene Delivery. Synthetic Commun 2010; 40: 1802-11.
92. Qin Z, Liu W, Li L, et al. Galactosylated N-2-hydroxypropyl methacrylamide-b-N-3-guanidinopropyl methacrylamide block copolymers as hepatocyte-targeting gene carriers. Bioconjug Chem 2011; 22: 1503-12.
93. Hu HM, Zhang X, Zhong NQ, Pan SR. Study on galactosepoly(ethylene glycol)-poly(L-lysine) as novel gene vector for targeting hepatocytes in vitro. J Biomater Sci Polym Ed 2012; 23: 677-95.
94. Wang Y, Su J, Cai W, et al. Hepatocyte-targeting gene transfer mediated by galactosylated poly(ethylene glycol)-graftpolyethylenimine derivative. Drug Des Devel Ther 2013; 7: 211-21.
95. Ishihara T, Kano A, Obara K, et al. Nuclear localization and antisense effect of PNA internalized by ASGP-R-mediated endocytosis with protein/DNA conjugates. J Control Release 2011; 155: 34-9.
96. Oishi M, Nagatsugi F, Sasaki S, Nagasaki Y, Kataoka K. Smart polyion complex micelles for targeted intracellular delivery of PEGylated antisense oligonucleotides containing acid-labile linkages. Chembiochem 2005; 6: 718-25.
97. Nie C, Liu C, Chen G, et al. Hepatocyte-targeted psiRNA delivery mediated by galactosylated poly(ethylene glycol)-graftpolyethylenimine in vitro. J Biomater Appl 2011; 26: 255-75.
98. Jiang HL, Kwon JT, Kim YK, et al. Galactosylated chitosan-graftpolyethylenimine as a gene carrier for hepatocyte targeting. Gene Ther 2007; 14: 1389-98.
99. Jiang HL, Kwon JT, Kim EM, et al. Galactosylated poly(ethylene glycol)-chitosan-graft-polyethylenimine as a gene carrier for hepatocyte-targeting. J Control Release 2008; 131: 150-7.
100. Kim JH, Minai-Tehrani A, Kim YK, et al. Suppression of tumor growth in H-ras12V liver cancer mice by delivery of programmed cell death protein 4 using galactosylated poly(ethylene glycol)-chitosan-graft-spermine. Biomaterials 2012; 33: 1894-902.
101. Patri AK, Majoros IJ, Baker JR. Dendritic polymer macromolecular carriers for drug delivery. Curr Opin Chem Biol 2002; 6: 466-71.
102. Hayashi Y, Mori Y, Higashi T, et al. Systemic delivery of transthyretin siRNA mediated by lactosylated dendrimer/alphacyclodextrin conjugates into hepatocyte for familial amyloidotic polyneuropathy therapy. Amyloid 2012; 19 Suppl 1: 47-9.
103. Hayashi Y, Higashi T, Motoyama K, et al. Design and evaluation of polyamidoamine dendrimer conjugate with PEG, alphacyclodextrin and lactose as a novel hepatocyte-selective gene carrier in vitro and in vivo. J Drug Target 2013; 21: 487-96.
104. Jeong Y-I, Seo S-J, Park I-K, et al. Cellular recognition of paclitaxel-loaded polymeric nanoparticles composed of poly(--benzyl l-glutamate) and poly(ethylene glycol) diblock copolymer endcapped with galactose moiety. Int J Pharm 2005; 296: 151-61.
105. Liang HF, Yang TF, Huang CT, Chen MC, Sung HW. Preparation of nanoparticles composed of poly(gamma-glutamic acid)-poly(lactide) block copolymers and evaluation of their uptake by HepG2 cells. J Control Release 2005; 105: 213-25.
106. Hiratsuka T, Goto M, Kondo Y, Cho CS, Akaike T. Copolymers for hepatocyte-specific targeting carrying galactose and hydrophobic alkyl groups. Macromol Biosci 2008; 8: 231-8.
107. Yang R, Meng F, Ma S, et al. Galactose-decorated cross-linked biodegradable poly(ethylene glycol)-b-poly(epsilon-caprolactone) block copolymer micelles for enhanced hepatoma-targeting delivery of paclitaxel. Biomacromolecules 2011; 12: 3047-55.
108. Deming TJ. Synthetic polypeptides for biomedical applications. Prog Polym Sci 2007; 32: 858-75.
109. Bae Y, Kataoka K. Intelligent polymeric micelles from functional poly(ethylene glycol)-poly(amino acid) block copolymers. Adv Drug Deliv Rev 2009; 61: 768-84.
110. Lin A, Chen J, Liu Y, et al. Preparation and evaluation of Ncaproyl chitosan nanoparticles surface modified with glycyrrhizin for hepatocyte targeting. Drug Dev Ind Pharm 2009; 35: 1348-55.
111. Lin A, Liu Y, Huang Y, et al. Glycyrrhizin surface-modified chitosan nanoparticles for hepatocyte-targeted delivery. Int J Pharm 2008; 359: 247-53.
112. Tian Q, Wang W, He X, et al. Glycyrrhetinic acid-modified nanoparticles for drug delivery: Preparation and characterization. Chinese Sci Bull 2009; 54: 3121-6.
113. He ZY, Zheng X, Wu XH, et al. Development of glycyrrhetinic acid-modified stealth cationic liposomes for gene delivery. Int J Pharm 2010; 397: 147-54.
114. Tian Q, Zhang CN, Wang XH, et al. Glycyrrhetinic acid-modified chitosan/poly(ethylene glycol) nanoparticles for liver-targeted delivery. Biomaterials 2010; 31: 4748-56.
115. Guo H, Lai Q, Wang W, et al. Functional alginate nanoparticles for efficient intracellular release of doxorubicin and hepatoma carcinoma cell targeting therapy. Int J Pharm 2013; 451: 1-11.
116. Zhang C, Wang W, Liu T, et al. Doxorubicin-loaded glycyrrhetinic acid-modified alginate nanoparticles for liver tumor chemotherapy. Biomaterials 2012; 33: 2187-96.
117. Li J, Xu H, Ke X, Tian J. The anti-tumor performance of docetaxel liposomes surface-modified with glycyrrhetinic acid. J Drug Target 2012; 20: 467-73.
118. Zhang L, Yao J, Zhou J, Wang T, Zhang Q. Glycyrrhetinic acidgraft-hyaluronic acid conjugate as a carrier for synergistic targeted delivery of antitumor drugs. Int J Pharm 2013; 441: 654-64.
119. He G, He Z, Zheng X, et al. Synthesis, characterization and in vitro evaluation of self-assembled poly (ethylene glycol)-glycyrrhetinic acid conjugates. Lett Org Chem 2012; 9: 202-10.
120. Wang Y, Xu Z, Zhang R, et al. A facile approach to construct hyaluronic acid shielding polyplexes with improved stability and reduced cytotoxicity. Colloid Surface B 2011; 84: 259-66.
121. Han SE, Kang H, Shim GY, et al. Cationic derivatives of biocompatible hyaluronic acids for delivery of siRNA and antisense oligonucleotides. J Drug Target 2009; 17: 123-32.
122. Takei Y, Maruyama A, Ferdous A, et al. Targeted gene delivery to sinusoidal endothelial cells: DNA nanoassociate bearing hyaluronan-glycocalyx. FASEB J 2004; 18: 699-701.
123. Kim J, Kim KS, Jiang G, et al. In vivo real-time bioimaging of hyaluronic acid derivatives using quantum dots. Biopolymers 2008; 89: 1144-53.
124. Jiang G, Park K, Kim J, Kim KS, Hahn SK. Target specific intracellular delivery of siRNA/PEI-HA complex by receptor mediated endocytosis. Mol Pharm 2009; 6: 727-37.
125. Kim KS, Hur W, Park SJ, et al. Bioimaging for targeted delivery of hyaluronic Acid derivatives to the livers in cirrhotic mice using quantum dots. ACS Nano 2010; 4: 3005-14.
126. Li F, Li QH, Wang JY, et al. Effects of interferon-gamma liposomes targeted to platelet-derived growth factor receptor-beta on hepatic fibrosis in rats. J Control Release 2012; 159: 261-70.
127. Adrian JE, Kamps JA, Poelstra K, et al. Delivery of viral vectors to hepatic stellate cells in fibrotic livers using HVJ envelopes fused with targeted liposomes. J Drug Target 2007; 15: 75-82.
128. Gonzalo T, Talman EG, van de Ven A, et al. Selective targeting of pentoxifylline to hepatic stellate cells using a novel platinum-based linker technology. J Control Release 2006; 111: 193-203.
129. Asl MN, Hosseinzadeh H. Review of pharmacological effects of Glycyrrhiza sp. and its bioactive compounds. Phytother Res 2008; 22: 709-24.
130. Ming LJ, Yin AC. Therapeutic effects of glycyrrhizic acid. Nat Prod Commun 2013; 8: 415-8.
131. Nabekura T, Yamaki T, Ueno K, Kitagawa S. Inhibition of Pglycoprotein and multidrug resistance protein 1 by dietary phytochemicals. Cancer Chemother Pharmacol 2008; 62: 867-73.
132. Lee CS, Kim YJ, Lee MS, Han ES, Lee SJ. 18beta-Glycyrrhetinic acid induces apoptotic cell death in SiHa cells and exhibits a synergistic effect against antibiotic anti-cancer drug toxicity. Life Sci 2008; 83: 481-9.
133. Zong L, Qu Y, Xu MY, Dong YW, Lu LG. 18alpha-glycyrrhetinic acid down-regulates expression of type I and III collagen via TGFBeta1/ Smad signaling pathway in human and rat hepatic stellate cells. Int J Med Sci 2012; 9: 370-9.
134. Kuang P, Zhao W, Su W, et al. 18beta-glycyrrhetinic acid inhibits hepatocellular carcinoma development by reversing hepatic stellate cell-mediated immunosuppression in mice. Int J Cancer 2013; 132: 1831-41.
135. Patel DK, Prasad SK, Kumar R, Hemalatha S. An overview on antidiabetic medicinal plants having insulin mimetic property. Asian Pac J Trop Biomed 2012; 2: 320-30.
136. Maitraie D, Hung CF, Tu HY, et al. Synthesis, anti-inflammatory, and antioxidant activities of 18beta-glycyrrhetinic acid derivatives as chemical mediators and xanthine oxidase inhibitors. Bioorg Med Chem 2009; 17: 2785-92.
137. Kim HK, Park Y, Kim HN, et al. Antimicrobial mechanism of--glycyrrhetinic acid isolated from licorice, Glycyrrhiza glabra. Biotechnology letters 2002; 24: 1899-902.
138. Salari MH, Kadkhoda Z. In vitro antibacterial effects of glycyrrhetinic acid on periodontopathogenic and capnophilic bacteria isolated from adult periodontitis. Clin Microbiol Infect 2003; 9: 987-8.
139. Kalani K, Kushwaha V, Verma R, Murthy PK, Srivastava SK. Glycyrrhetinic acid and its analogs: a new class of antifilarial agents. Bioorg Med Chem Lett 2013; 23: 2566-70.
140. Fiore C, Eisenhut M, Krausse R, et al. Antiviral effects of Glycyrrhiza species. Phytother Res 2008; 22: 141-8.
141. Shetty AV, Thirugnanam S, Dakshinamoorthy G, et al. 18alphaglycyrrhetinic acid targets prostate cancer cells by down-regulating inflammation-related genes. Int J Oncol 2011; 39: 635-40.
142. Zhao X, Fan Y, Wang D, et al. Immunological adjuvant efficacy of glycyrrhetinic acid liposome against Newcastle disease vaccine. Vaccine 2011; 29: 9611-7.
143. Kim ME, Kim HK, Kim DH, Yoon JH, Lee JS. 18beta-Glycyrrhetinic acid from licorice root impairs dendritic cells maturation and Th1 immune responses. Immunopharmacol Immunotoxicol 2013; 35: 329-35.
144. Tabuchi M, Imamura S, Kawakami Z, Ikarashi Y, Kase Y. The blood-brain barrier permeability of 18beta-glycyrrhetinic acid, a major metabolite of glycyrrhizin in Glycyrrhiza root, a constituent of the traditional Japanese medicine yokukansan. Cell Mol Neurobiol 2012; 32: 1139-46.
145. Toole BP. Hyaluronan-CD44 interactions in cancer: paradoxes and possibilities. Clin Cancer Res 2009; 15: 7462-8.
146. Haramaki M, Yano H, Fukuda K, et al. Expression of CD44 in human hepatocellular carcinoma cell lines. Hepatology 1995; 21: 1276-84.
147. Endo K, Terada T. Protein expression of CD44 (standard and variant isoforms) in hepatocellular carcinoma: relationships with tumor grade, clinicopathologic parameters, p53 expression, and patient survival. J Hepatol 2000; 32: 78-84.
148. Mochizuki S, Kano A, Shimada N, Maruyama A. Uptake of enzymatically-digested hyaluronan by liver endothelial cells in vivo and in vitro. J Biomater Sci Polym Ed 2009; 20: 83-97.
149. Ruoslahti E, Bhatia SN, Sailor MJ. Targeting of drugs and nanoparticles to tumors. J Cell Biol 2010; 188: 759-68.
150. Choi KY, Saravanakumar G, Park JH, Park K. Hyaluronic acidbased nanocarriers for intracellular targeting: interfacial interactions with proteins in cancer. Colloid Surface B 2012; 99: 82-94.
151. Luo Y, Ziebell MR, Prestwich GD. A hyaluronic acid-taxol antitumor bioconjugate targeted to cancer cells. Biomacromolecules 2000; 1: 208-18.
152. Luo Y, Bernshaw NJ, Lu ZR, Kopecek J, Prestwich GD. Targeted delivery of doxorubicin by HPMA copolymer-hyaluronan bioconjugates. Pharm Res 2002; 19: 396-402.
153. Kim SJ, Hahn SK, Kim MJ, Kim DH, Lee YP. Development of a novel sustained release formulation of recombinant human growth hormone using sodium hyaluronate microparticles. J Control Release 2005; 104: 323-35.
154. Motokawa K, Hahn SK, Nakamura T, Miyamoto H, Shimoboji T. Selectively crosslinked hyaluronic acid hydrogels for sustained release formulation of erythropoietin. J Biomed Mater Res A 2006; 78: 459-65.
155. Oh EJ, Park K, Kim KS, et al. Target specific and long-acting delivery of protein, peptide, and nucleotide therapeutics using hyaluronic acid derivatives. J Control Release 2010; 141: 2-12.
156. Liu Y, Kong M, Cheng XJ, et al. Self-assembled nanoparticles based on amphiphilic chitosan derivative and hyaluronic acid for gene delivery. Carbohydr Polym 2013; 94: 309-16.
157. Kim KS, Kim S, Beack S, et al. In vivo real-time confocal microscopy for target-specific delivery of hyaluronic acid-quantum dot conjugates. Nanomedicine 2012; 8: 1070-3.
158. Goh EJ, Kim KS, Kim YR, et al. Bioimaging of hyaluronic acid derivatives using nanosized carbon dots. Biomacromolecules 2012; 13: 2554-61.
159. Bhang SH, Won N, Lee TJ, et al. Hyaluronic acid-quantum dot conjugates for in vivo lymphatic vessel imaging. ACS Nano 2009; 3: 1389-98.
160. Cho HJ, Yoon HY, Koo H, et al. Hyaluronic acid-ceramide-based optical/MR dual imaging nanoprobe for cancer diagnosis. J Control Release 2012; 162: 111-8.
161. Ossipov DA. Nanostructured hyaluronic acid-based materials for active delivery to cancer. Expert Opin Drug Deliv 2010; 7: 681-703.
162. Rosso F, Quagliariello V, Tortora C, et al. Cross-linked hyaluronic acid sub-micron particles: in vitro and in vivo biodistribution study in cancer xenograft model. J Mater Sci Mater Med 2013; 24: 1473-81.
163. Lee SJ, Ghosh SC, Han HD, et al. Metronomic activity of CD44-targeted hyaluronic acid-paclitaxel in ovarian carcinoma. Clin Cancer Res 2012; 18: 4114-21.
164. Choi KY, Min KH, Yoon HY, et al. PEGylation of hyaluronic acid nanoparticles improves tumor targetability in vivo. Biomaterials 2011; 32: 1880-9.
165. Furumoto K, Nagayama S, Ogawara K, et al. Hepatic uptake of negatively charged particles in rats: possible involvement of serum proteins in recognition by scavenger receptor. J Control Release 2004; 97: 133-41.
166. Terpstra V, van Amersfoort ES, van Velzen AG, Kuiper J, van Berkel TJ. Hepatic and extrahepatic scavenger receptors: function in relation to disease. Arterioscler Thromb Vasc Biol 2000; 20: 1860-72.
167. Li JY, Paragas N, Ned RM, et al. SCARA5 is a ferritin receptor mediating non-transferrin iron delivery. Dev Cell 2009; 16: 35-46.
168. Huang J, Zheng DL, Qin FS, et al. Genetic and epigenetic silencing of SCARA5 may contribute to human hepatocellular carcinoma by activating FAK signaling. J Clin Invest 2010; 120: 223-41.
169. Geninatti Crich S, Cutrin JC, Lanzardo S, et al. Mn-loaded apoferritin: a highly sensitive MRI imaging probe for the detection and characterization of hepatocarcinoma lesions in a transgenic mouse model. Contrast Media Mol Imaging 2012; 7: 281-8.
170. Yan F, Zhang Y, Yuan HK, Gregas MK, Vo-Dinh T. Apoferritin protein cages: a novel drug nanocarrier for photodynamic therapy. Chem Commun (Camb) 2008: 4579-81.
171. Kim SI, Shin D, Choi TH, et al. Systemic and specific delivery of small interfering RNAs to the liver mediated by apolipoprotein A-I. Mol Ther 2007; 15: 1145-52.
172. Liu X, Suo R, Xiong SL, Zhang QH, Yi GH. HDL drug carriers for targeted therapy. Clin Chim Acta 2013; 415: 94-100.
173. Nagayama S, Ogawara K, Minato K, et al. Fetuin mediates hepatic uptake of negatively charged nanoparticles via scavenger receptor. Int J Pharm 2007; 329: 192-8.
174. Kawaguchi R, Yu J, Honda J, et al. A membrane receptor for retinol binding protein mediates cellular uptake of vitamin A. Science 2007; 315: 820-5.
175. Kawaguchi R, Zhong M, Kassai M, Ter-Stepanian M, Sun H. Differential and isomer-specific modulation of vitamin A transport and the catalytic activities of the RBP receptor by retinoids. J Membr Biol 2013; 246: 647-60.
176. Rosenbaum J. Vitamin A-guided siRNAs targeting a collagen chaperone can reverse experimental cirrhosis. J Hepatol 2008; 49: 1085-7.
177. Ishida Y, Nagata K. Hsp47 as a collagen-specific molecular chaperone. Methods Enzymol 2011; 499: 167-82.
178. Adrian JE, Poelstra K, Scherphof GL, et al. Effects of a new bioactive lipid-based drug carrier on cultured hepatic stellate cells and liver fibrosis in bile duct-ligated rats. J Pharmacol Exp Ther 2007; 321: 536-43.
179. Son G, Hines IN, Lindquist J, Schrum LW, Rippe RA. Inhibition of phosphatidylinositol 3-kinase signaling in hepatic stellate cells blocks the progression of hepatic fibrosis. Hepatology 2009; 50: 1512-23.
180. Shim AH, Liu H, Focia PJ, et al. Structures of a platelet-derived growth factor/propeptide complex and a platelet-derived growth factor/receptor complex. Proc Natl Acad Sci USA 2010; 107: 11307-12.
181. Cao Y, Cao R, Hedlund EM. R Regulation of tumor angiogenesis and metastasis by FGF and PDGF signaling pathways. J Mol Med (Berl) 2008; 86: 785-9.
182. Pinzani M, Milani S, Herbst H, et al. Expression of platelet-derived growth factor and its receptors in normal human liver and during active hepatic fibrogenesis. Am J Pathol 1996; 148: 785-800.
183. Fredriksson L, Li H, Eriksson U. The PDGF family: four gene products form five dimeric isoforms. Cytokine Growth FR 2004; 15: 197-204.
184. Beljaars L, Weert B, Geerts A, Meijer DKF, Poelstra K. The preferential homing of a platelet derived growth factor receptorrecognizing macromolecule to fibroblast-like cells in fibrotic tissue. Biochem Pharmacol 2003; 66: 1307-17.
185. York SJ, Arneson LS, Gregory WT, Dahms NM, Kornfeld S. The rate of internalization of the mannose 6-phosphate/insulin-like growth factor II receptor is enhanced by multivalent ligand binding. J Biol Chem 1999; 274: 1164-71.
186. Beljaars L, Molema G, Schuppan D, et al. Successful targeting to rat hepatic stellate cells using albumin modified with cyclic peptides that recognize the collagen type VI receptor. J Biol Chem 2000; 275: 12743-51.
187. Adrian JE, Poelstra K, Scherphof GL, et al. Interaction of targeted liposomes with primary cultured hepatic stellate cells: Involvement of multiple receptor systems. J Hepatol 2006; 44: 560-7.
188. Satelli A, Li S. Vimentin in cancer and its potential as a molecular target for cancer therapy. Cell Mol Life Sci 2011; 68: 3033-46.
189. Komura K, Ise H, Akaike T. Dynamic behaviors of vimentin induced by interaction with GlcNAc molecules. Glycobiology 2012; 22: 1741-59.
190. Ghosh S, Ahrens WA, Phatak SU, et al. Association of filamin A and vimentin with hepatitis C virus proteins in infected human hepatocytes. J Viral Hepat 2011; 18: e568-77.
191. Ivaska J, Pallari HM, Nevo J, Eriksson JE. Novel functions of vimentin in cell adhesion, migration, and signaling. Exp Cell Res 2007; 313: 2050-62.
192. Ise H, Kobayashi S, Goto M, et al. Vimentin and desmin possess GlcNAc-binding lectin-like properties on cell surfaces. Glycobiology 2010; 20: 843-64.
193. Ise M, Ise H, Shiba Y, et al. Targeting N-acetylglucosaminebearing polymer-coated liposomes to vascular smooth muscle cells. J Artif Organs 2011; 14: 301-9.
194. Kim SJ, Ise H, Goto M, Akaike T. Interactions of vimentin-or desmin-expressing liver cells with N-acetylglucosamine-bearing polymers. Biomaterials 2012; 33: 2154-64.
195. Cheng K, Ye Z, Guntaka RV, Mahato RI. Enhanced hepatic uptake and bioactivity of type alpha1(I) collagen gene promoter-specific triplex-forming oligonucleotides after conjugation with cholesterol. J Pharmacol Exp Ther 2006; 317: 797-805.
196. East L, Isacke CM. The mannose receptor family. Biochim Biophys Acta 2002; 1572: 364-86.
197. Weis WI, Taylor ME, Drickamer K. The C-type lectin superfamily in the immune system. Immunol Rev 1998; 163: 19-34.
198. Gazi U, Martinez-Pomares L. Influence of the mannose receptor in host immune responses. Immunobiology 2009; 214: 554-61.
199. Ohnishi H, Oka K, Mizuno S, Nakamura T. Identification of mannose receptor as receptor for hepatocyte growth factor betachain: novel ligand-receptor pathway for enhancing macrophage phagocytosis. J Biol Chem 2012; 287: 13371-81.
200. Kawao N, Nagai N, Tamura Y, et al. Urokinase-type plasminogen activator contributes to heterogeneity of macrophages at the border of damaged site during liver repair in mice. Thromb Haemost 2011; 105: 892-900.